PPT-Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding

Paul P Dobesh PharmD FCCP BCPS BCCP Professor of Pharmacy Practice and Science University of Nebraska Medical Center College of Pharmacy Omaha Nebraska USA Disclosures Consultant for the follow entities. Andrew McDonald. Alberts Cellular Therapy. “All bleeding eventually stops”. n. Modified Virchow’s triad. BLEEDING. Blood flow. Size. BP. Vessel wall. Endothelial activation. Collagen disorders. Tx. : . Real-World Practice. In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx. 1. Patients on chronic OAC with CAD are 7x more likely to receive concomitant antiplatelet tx. Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Brandon . McMahon,. MD. Venous . Thromboembolism. (VTE). ~950,000 cases of VTE annually (incident + recurrent). Rates expected to double by 2050. Mortality. 100,000 US deaths annually. 10-30% die within a month of diagnosis. . . Feb 08/2014. Hanadi. . Alhozali,MBBS,ABIM,FRCPC. Assistant professor consultant internal medicine and Nephrology KAUH/Jeddah. Glomerular- based disease and Renal disease in pregnancy. Objectives. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. . . Feb 08/2014. Hanadi. . Alhozali,MBBS,ABIM,FRCPC. Assistant professor consultant internal medicine and Nephrology KAUH/Jeddah. Glomerular- based disease and Renal disease in pregnancy. Objectives. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Introduction/Overview . VKA-Associated Bleeding: . Results From the RADOA Registry . Reversal Agents for VKA-Associated Anticoagulation. Management of Urgent Anticoagulation Reversal: . 4F-PCC vs FFP. Fibrillation. Michelle Tsukamoto . DSR 2 May 9, 2018. PGY 2. 1. Objectives. Discuss which patients with . atrial. fibrillation should be . anticoagulated. for CVA prevention. Learn about different oral anticoagulation options . Fibrillation. Michelle Tsukamoto . DSR 2 May 9, 2018. PGY 2. 1. Objectives. Discuss which patients with . atrial. fibrillation should be . anticoagulated. for CVA prevention. Learn about different oral anticoagulation options . Presenter: . Meng-Jiun. . Chiou. 5Sep2017. 1. Introduction. Lifelong . antiplatelet. treatment is recommended after . ischaemic. vascular events, on the basis of trials done mainly in patients younger than 75 years. . Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . OHHI Cardiology Group. Antiplatelet and Anticoagulation Therapy – What You Need to Know. Objectives. Utilize current practice guidelines for the management of antiplatelet therapy in CAD patients..